urine samples collected during pregnancy. Therapy was not directly observed. An early test of cure period was defined as the first test 3-6 weeks after the initial positive test. The late CT testing period was defined as >6 weeks after the initial positive test and "any positive" was compared to "never positive" for women with >1 CT test. Descriptive characteristics with 95% confidence intervals were used to compute rates of persistent/recurrent CT infection. RESULTS: At our center, 77% (16,138/20946 ) of deliveries among 13,692 women had CT testing performed during pregnancy. Among these 16,138 deliveries, 1526 (9.5%; 95% CI 9.0-9.9%) had CT detected. Compared to women without CT, women with CT were significantly younger, more likely to be Black and to have public insurance. (Table 1 ) Early repeat CT testing was performed in 57% of CT cases and 11.6% (95% CI 9.4-13.7%) (99/857) were persistently positive. (Fig 1) Incident chamydia (reinfection was detected in 14% (75/525) of those with a negative early test of cure. Among pregnancies with follow up CT testing only later in pregnancy, 27% (119/446) had a subsequent positive CT test. CONCLUSION: Chlamydia infection was common among pregnant women screened at our urban center with a disproportionate impact on young women and Black women. Persistent/recurrent and incident CT rates were elevated at early and late time periods at rates that surpass those in non-pregnant women. Potential reasons for CT persistence/reinfection in this cohort include poor adherence or non-response to standard antibiotic therapy, altered host immunity in pregnancy or lack of partner therapy. OBJECTIVE: Prophylaxis starting at 36 weeks has been shown to reduce the rate of cesarean delivery (CD) in patients with a history of recurrent herpes simplex virus (HSV). However, guidelines do not differentiate between patients who are planning a scheduled CD at term and those who are planning to labor. The objective of this study was to examine whether HSV prophylaxis in patients planning to deliver by CD is cost-effective. STUDY DESIGN: This was a cost-effectiveness analysis from the societal perspective comparing antiviral prophylaxis to no treatment in patients with a history of recurrent HSV planning to deliver by CD. Costs in 2018 US $, utilities, and probabilities were derived from the literature. We assumed that 96.7% of patients planning on CD would deliver by CD, and that CD would reduce the rate of neonatal HSV by 85% compared to vaginal delivery (VD). We included asymptomatic shedding in the model because this is associated with neonatal HSV. We modeled neonatal outcomes including no HSV, central nervous system HSV, and skin, eyes, and mouth HSV, and included hospital costs for neonates (including neonatal screening in cases of maternal outbreak but asymptomatic neonate) as well as education or institutional costs and future health care costs up to age 20. Utilities were measured in qualityadjusted life years (QALY) assuming a life expectancy of 20 years for severe disability and 78.8 years for all other neonates. Costs and QALYs were discounted 3%, and the willingness-to-pay (WTP) threshold was $100,000/QALY. Deterministic 1-way sensitivity analyses were performed. RESULTS: Prophylaxis reduced expected costs by $241, increased QALYs by 0.0045, and reduced the incidence of neonatal HSV from 83/100,000 to 25/100,000. Although prophylaxis became the more costly strategy at a drug cost of $256, at the WTP prophylaxis remained cost-effective until the drug cost was > $703. The model was not sensitive to the rate of CD or the reduction in HSV from CD versus VD. If prophylaxis reduced the rate of neonatal HSV by <2%, then it would no longer be cost-effective. CONCLUSION: Despite the relative rarity of neonatal HSV in offspring of patients with a history of recurrent HSV, prophylaxis in patients planning on CD is cost-effective across a wide range of assumptions. Notably, prophylaxis has never been shown in trials to reduce the rate of neonatal HSV, but even if it only reduces the rate by at least 2% it would be cost-effective in this population. STUDY DESIGN: This is a prospective IRB-approved cohort study of 29 pregnant women with a singleton pregnancy <14 weeks. Exclusion criteria included recurrent UTI, antibiotic use since conception, and urinary tract anomalies. During their 1 st trimester visit, consented subjects provided paired clean catch urine and vaginal swab samples. Samples were assessed by an Expanded Quantitative Culture (EQC) method that -compared to the standard urine culture method -uses more types of media and atmospheric conditions with a longer incubation period. Colony forming units (CFU) were counted for each morphologically distinct colony type; representative colonies were purified for identification using MALDI-TOF Mass Spectroscopy. Species identification and CFU counts were combined for analysis using the Bray-Curtis dissimilarity index (BC). A BC value of 0.5 was used to sort paired vaginal and urine samples as similar (<0.5) or different (0.5). For descriptive purposes, samples were hierarchically clustered with complete-linkage agglomeration by their vaginal culture results. RESULTS: The majority of the subjects were multiparous (n¼20) with a mean age of 29.6 years. EQC detected live microbes in both urine and vaginal samples of all subjects. The vaginal samples clustered into 4 distinct community state structures (Figure) . Based on BC indices, paired urine and vaginal samples were dissimilar (BC0.5) for 72% (n¼21) of subjects. Of the 8 subjects with similar urine and vaginal microbiomes (BC<0.5), Lactobacillus was dominant in 88% of vaginal samples (n¼7) and 100% of urine samples (n¼8). In contrast, of the 21 subjects with dissimilar microbiomes (BC>0.5), a minority (24%, n¼5) had a Lactobacillus-dominant urine sample (p<0.01). CONCLUSION: The clean catch urine microbiome of pregnant women in their 1 st trimester is most often distinct from their vaginal microbiome, evidence that their lower urinary tract contains a unique microbiome. Women with dissimilar urine and vaginal microbiomes were less likely to have Lactobacillus-dominant urine. Given these findings, the vaginal microbiome should not be assumed to represent the lower urinary tract microbiome.
